Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 17,835 matching trials from the live ClinicalTrials.gov search.
Conditions
Migraine
Interventions
Hydromorphone, Prochlorperazine, Diphenhydramine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Multiple Sclerosis
Interventions
intrathecal administration of autologous MSC-NP
Biological
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Asthma
Interventions
TEV-56248, Fp MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Mobile, Alabama • Long Beach, California • Miami, Florida + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

NCT05138653
Conditions
Healthy Participants
Interventions
CVL-354, Placebo
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
Interventions
Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Renal Colic, Kidney Stone
Interventions
Erector Spinae Plane Block (ESPB), Ropivacaine
Procedure · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Early Phase 1 Interventional Accepts healthy volunteers

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

NCT03647202
Conditions
Food Effects on Pharmacokinetics
Interventions
Milademetan Treatment A, Milademetan Treatment B, Milademetan Treatment C
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions
medrol dosepak, HYDROcodone Oral Tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)

NCT02410902
Conditions
Autism
Interventions
CM-AT, PLACEBO
Drug
Lead sponsor
Curemark
Industry
Eligibility
3 Years to 8 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Conditions
Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
Interventions
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
25,236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
156
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Conditions
Lymphoma
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults

NCT07831473
Conditions
Randomised Clinical Trial, Double Blind, Dengue, Challenge Test, Dose Escalation and Safety
Interventions
VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant, ALFQ adjuvant + Saline, rDEN3Delta30
Biological
Lead sponsor
VLP Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects

NCT01701505
Conditions
Anesthesia
Interventions
400uL of Kovacaine Mist, 200uL of Kovacaine Mist, 120uL of Kovacaine Mist
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Malignant Glioma
Interventions
LBH589, bevacizumab
Drug
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Charlottesville, Virginia
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Huntington Beach, California • Pomona, California • Jacksonville, Florida + 21 more
Conditions
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions
AOC 1001, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Completed Not applicable Interventional Results available

Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors

NCT00972205
Conditions
Cervical, Ovarian, Lung, Breast, Renal
Interventions
paclitaxel, CBT-1(Registered Trademark), Tc 99m sestamibi
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab, Fludarabine
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more